

Medical drug benefit *Clinical Criteria* updates

On September 22, 2021, and November 19, 2021, the Pharmacy and Therapeutics (P&T) Committee approved the following *Clinical Criteria* applicable to the **medical drug benefit** for Anthem Blue Cross. These policies were developed, revised, or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. If you have questions or would like additional information, use this [email](#).

See the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) denote that the criteria may be perceived as more restrictive

Share this notice with other members of your practice and office staff.

Please note: The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical policy. This does not apply to pharmacy services.

Effective date	Document number	<i>Clinical Criteria</i> title	New or revised
May 11, 2022	*ING-CC-0204	Tivdak (tisotumab vedotin-tftv)	New
May 11, 2022	*ING-CC-0018	Lumizyme (alglucosidase alfa); Nexviazyme (avalglucosidase alfa-ngpf)	Revised
May 11, 2022	*ING-CC-0128	Tecentriq (atezolizumab)	Revised
May 11, 2022	*ING-CC-0012	Brineura (cerliponase alfa)	Revised
May 11, 2022	*ING-CC-0021	Fabrazyme (agalsidase beta)	Revised
May 11, 2022	*ING-CC-0017	Xiaflex (collagenase clostridium histolyticum)	Revised
May 11, 2022	*ING-CC-0026	Testosterone Injectable	Revised
May 11, 2022	*ING-CC-0100	Istodax (romidepsin)	Revised
May 11, 2022	*ING-CC-0125	Opdivo (nivolumab)	Revised
May 11, 2022	ING-CC-0197	Jemperli (dostarlimab-gxly)	Revised
May 11, 2022	ING-CC-0124	Keytruda (pembrolizumab)	Revised
May 11, 2022	*ING-CC-0061	GnRH Analogs for the Treatment of Non-Oncologic Indications	Revised
May 11, 2022	*ING-CC-0148	Agents for Hemophilia B	Revised
May 11, 2022	*ING-CC-0149	Select Clotting Agents for Bleeding Disorders	Revised
May 11, 2022	*ING-CC-0065	Agents for Hemophilia A and von Willebrand Disease	Revised

<https://providers.anthem.com/ca>

Effective date	Document number	<i>Clinical Criteria</i> title	New or revised
May 11, 2022	ING-CC-0168	Tecartus (brexucabtagene autoleucel)	Revised
May 11, 2022	*ING-CC-0195	Abecma (idecabtagene vicleucel)	Revised
May 11, 2022	*ING-CC-0001	Erythropoiesis Stimulating Agents	Revised
May 11, 2022	*ING-CC-0173	Enspryng (satralizumab-mwge)	Revised
May 11, 2022	*ING-CC-0170	Uplizna (inebilizumab-cdon)	Revised
May 11, 2022	*ING-CC-0041	Complement Inhibitors	Revised
May 11, 2022	*ING-CC-0071	Entyvio (vedolizumab)	Revised
May 11, 2022	*ING-CC-0064	Interleukin-1 Inhibitors	Revised
May 11, 2022	*ING-CC-0042	Monoclonal Antibodies to Interleukin-17	Revised
May 11, 2022	*ING-CC-0066	Monoclonal Antibodies to Interleukin-6	Revised
May 11, 2022	*ING-CC-0050	Monoclonal Antibodies to Interleukin-23	Revised
May 11, 2022	*ING-CC-0078	Orencia (abatacept)	Revised
May 11, 2022	*ING-CC-0063	Stelara (ustekinumab)	Revised
May 11, 2022	*ING-CC-0062	Tumor Necrosis Factor Antagonists	Revised
May 11, 2022	ING-CC-0003	Immunoglobulins	Revised
May 11, 2022	*ING-CC-0049	Radicava (edaravone)	Revised
May 11, 2022	*ING-CC-0075	Rituximab Agents for Non-Oncologic Indications	Revised
May 11, 2022	*ING-CC-0072	Selective Vascular Endothelial Growth Factor (VEGF) Antagonists	Revised
May 11, 2022	ING-CC-0107	Bevacizumab for Non-Ophthalmologic Indications	Revised
May 11, 2022	ING-CC-0106	Erbitux (cetuximab)	Revised
May 11, 2022	ING-CC-0105	Vectibix (panitumumab)	Revised
May 11, 2022	ING-CC-0043	Monoclonal Antibodies to Interleukin-5	Revised
May 11, 2022	*ING-CC-0068	Growth Hormone	Revised



Email is the quickest and most direct way to receive important information from Anthem Blue Cross.

To start receiving email from us (including some sent in lieu of fax or mail), submit your information using the QR code to the right or via our online form (<https://bit.ly/3Lgko8>).

